← Compound index
COMPOUND RECORD / ENDOLUTEN

EndolutenЭндолутен

An animal pineal-gland peptide mixture used in the Gazprom occupational research program.

Source linked

What the studies found

Comparison in people · 2017

Tireogen and Endoluten as adjuncts in autoimmune thyroiditis

Study of multiple preparations

TSH at month four
Standard care 7.14 ± 0.86, Tireogen 4.09 ± 0.12, combination 3.94 ± 0.12 mIU/L. Shared baseline 8.84 ± 1.09.The table marks both adjunctive arms as significantly different from standard care.
Anti-thyroglobulin antibodies
83.32 ± 3.28, 77.41 ± 1.18 and 18.91 ± 1.65 IU/L in the three groups, respectively.The table marks both adjunctive arms. The narrative describes no antibody effect with Tireogen alone.
Anti-thyroid peroxidase antibodies
361.24 ± 12.4, 357.23 ± 11.41 and 29.16 ± 2.54 IU/L, respectively. The table gives no significance mark for this row.

At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.

Study notes · methods, sources and limitations

Participants or model 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.

Design 89 patients received standard treatment, 42 added Tireogen and 87 added Tireogen plus Endoluten. The reported schedules were two Tireogen capsules daily and one Endoluten capsule every three days for four months. Capsule mass is unspecified. The levothyroxine unit in the reproduction is anomalous.

Important limitations

  • Allocation, masking and separate baseline values are unspecified. There was no Endoluten-only arm. The table marks an anti-thyroglobulin difference for Tireogen alone, while the narrative says Tireogen alone did not affect antibodies. The anti-TPO row gives no significance mark. The reproduction prints an anomalous levothyroxine unit. The exact background dose is uncertain.
  • The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The design leaves allocation unspecified and the table gives one shared baseline.

Innovation in Aging. 2017;1(Suppl 1):324. PMCID PMC6243877. · Published conference abstract with author report

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Comparison in people · 2019

Zhenoluten and Endoluten in women with reduced reproductive function

Study of multiple preparations

Anti-Müllerian hormone at month four
1.16 ± 0.18 ng/mL with the combination versus 0.82 ± 0.24 with placebo. Baselines were 0.76 ± 0.13 and 0.74 ± 0.12 ng/mL, respectively.
Estradiol at month four
616.24 ± 69.42 pmol/L with the combination versus 209.26 ± 12.64 with placebo.
Pregnancies reported by months four through eight
180/214 (84%) with the combination versus 8/62 (13%) with placebo. The expanded report supplies no live-birth outcomes or detailed follow-up accounting.

In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.

Study notes · methods, sources and limitations

Participants or model 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.

Design From 2013 to 2018, the Moscow center enrolled 276 women aged 34–38. The 214-person combination arm received oral Zhenoluten 20 mg each morning and Endoluten 10 mg every 72 hours for four months. The 62-person comparison received placebo. Neither group received hormone therapy.

Important limitations

  • Group assignment and masking are unspecified. The report combines two products, so the effect of either alone is unknown. The pregnancy figures come from the authors’ expanded report. Live births, completeness of follow-up and maternal or neonatal safety data are unavailable. The conference methods and expanded report agree on every-72-hour Endoluten. A recommendation elsewhere in the conference reproduction gives a different schedule.
  • The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The differences come from a comparison with unspecified allocation and masking.

9th European Congress of the International Association of Gerontology and Geriatrics, Gothenburg, 2019. Author material reproduced by Peptides. · Conference report and expanded author report

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Comparison in people · 2011

Endoluten: clinical report on a tissue-derived preparation

Estradiol in the dyshormonal myocardial dystrophy subgroup
101.3 ± 7.2 pmol/L with Endoluten versus 79.1 ± 4.2 pmol/L with conventional care. Shared baseline 65.4 ± 5.2 pmol/L.Table 2 marks p < 0.05 versus conventional care.
Follicle-stimulating hormone in the same subgroup
46.8 ± 3.9 versus 71.6 ± 6.3 IU/mL, in the source’s printed units. Shared baseline 89.3 ± 3.5.Table 2 marks p < 0.05 versus conventional care.

In the dyshormonal myocardial dystrophy subgroup, estradiol was 101.3 pmol/L after Endoluten and 79.1 pmol/L after usual care. The report assessed several diagnoses separately.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.

Design 163 patients across four diagnoses, 99 receiving adjunctive Endoluten and 64 conventional care. Courses were one to three capsules two to three times daily for 15–30 days.

Important limitations

  • Subgroups must not be pooled into one efficacy result. This oral-preparation report cannot inherit long-term Epithalamin mortality findings. The linked page commercially reproduces the report. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
  • The subgroup outcomes are short-term hormone measurements. The report does not explain the allocation method.

Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗
01 / OVERVIEW

About Endoluten

Identity / background source ↗

Research background

Pineal-derived low-molecular-weight peptide mixture named in the original 113-worker Gazprom program. The paper reports program-level sick leave, without an Endoluten-specific effect.

More study findings

Observational study · 2016

Personified prevention of diseases under the conditions of the Far North

Study of multiple preparations

Sick-leave certificates
18 → 102014 → 2015; whole program
Days unfit for work
119 → 602014 → 2015; whole program
Seasonal morbidity
No statistically reliable improvement reported

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

More reported outcomes
Narrative/table discrepancy
Narrative 43.4% decrease; Table 2 gives 119 → 60 daysUnresolved source discrepancy; not interchangeable figures
Study notes · methods, sources and limitations

Participants or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Design 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Important limitations

  • One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Vrach. 2016;(6):64–66 · Journal publication

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Included in a 113-worker personalized program; no product-specific control arm

Study methods

Original 2016 PDF and historical institute reports

Independent replication

Independent replication not established in this collection

Source access

Primary-publication records linked; full-text versus abstract review shown per source

Safety evidence

Short-term reports do not establish long-term safety or equivalence to current products

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The 2016 Gazprom report lists Endoluten and provides program-wide outcomes. Its text reports a 43.4% reduction, while the table shows 119 to 60 days. Controlled results for Endoluten itself remain unavailable.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2016 · RU2589265C2 · Endoluten plus Chonsurid: dental bone-healing methodUse · 20 mm defect: healing at 6.5 months; density 206 HU

Reported findings

The Endoluten case had higher final density but a longer reported healing time; the examples do not demonstrate faster healing.

Endoluten adjunct case
20 mm defect: healing at 6.5 months; density 206 HUOne 66-year-old patient
Chonsurid-only example
17 mm defect: healing at 4 months; density 177 HUOne 65-year-old patient
All reported results, comparisons and limitations →

Use. The patent identifies branded Endoluten in combination with Chonsurid and dental treatment.

Endoluten is not automatically Epitalon or Epithalamin; the method cannot isolate the extract's contribution.

Publication
RU2589265C2 ↗ · 2016-07-10
Earliest priority / filing
2014-10-20 / 2014-10-20
Original applicant / assignee
Андрей Константинович Иорданишвили
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
55959663 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method of accelerating process of reparative osteogenesis

Inventors: Андрей Константинович Иорданишвили; Антон Анатольевич Сериков; Дмитрий Викторович Балин; Анна Геннадьевна Слугина; Владимир Владимирович Самсонов; Борис Лаврович Макеев; Людмила Юрьевна Орехова.

RU2589265C2

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2013

Suprefort with and without Cerluten and Endoluten in type 2 diabetes

The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.

Study notes and original source
2013Human comparative studyRussian-language source

Suprefort with and without Cerluten and Endoluten in type 2 diabetes

Oral pancreas, brain and pineal polypeptide preparations added to standard therapy · Conference report · company reproduction

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.

The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.

Results and tables

Reported findings and study design

Moscow, February 2011 to April 2012. Standard treatment alone (329), plus Suprefort (214), or plus Suprefort, Cerluten and Endoluten (375). Suprefort and Cerluten were given orally as two capsules each per day for three months. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified in this source.

Population or model 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.

Results · Russian conference reproduction, pp. 11–13, and matching English edition
MeasureResultComparison, timing and statistics
Glucose two hours after challenge9.7 ± 0.5 mmol/L with standard care, 7.3 ± 0.6 with added Suprefort, 6.5 ± 0.4 with the three-product combination.Both adjunctive arms are marked significant versus standard care. Exact p values are unavailable.
Fasting glucose6.8 ± 0.6, 6.1 ± 0.5 and 5.6 ± 0.4 mmol/L, respectively.Both adjunctive arms are marked significant versus standard care.
Standard medication dose reportedly reduced0/329 standard care, 114/214 (53.3%) added Suprefort, 279/375 (74.4%) three-product combination.Medication-adjustment criteria and timing are unspecified.
Glucose response countsSuprefort arm: 195/214 (91.1%) reached the reported upper normal limit by day 18. Three-product arm: 348/375 (92.8%) reportedly normalized by day 12.These outcomes use different assessment days and wording.
Blood glucose in the three reported groups
Blood glucose in the three reported groups
Treatment groupParticipantsFasting beforeFasting afterTwo-hour beforeTwo-hour after
Standard care3298.4 ± 0.66.8 ± 0.613.8 ± 0.49.7 ± 0.5
Standard care + Suprefort2148.2 ± 0.76.1 ± 0.513.4 ± 0.67.3 ± 0.6
Standard care + Suprefort, Cerluten and Endoluten3758.3 ± 0.75.6 ± 0.413.6 ± 0.66.5 ± 0.4

Glucose in mmol/L. Table 3 leaves the timing and the meaning of the ± term unspecified.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. The reports do not give a systematic harms assessment. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
Source reviewed
Authors’ conference material, Russian reproduction, PDF pages 11–13, methods and Table 3. English and Russian editions describe the same cohort.
Study limitations
  • Allocation, masking, treatment adjustments, exact timing of Table 3 and analysis denominators are unspecified. The response counts use different assessment days.
  • The 918-person Moscow comparison has a different site and design from the 59-person St. Petersburg Medical Center report. Participant-level linkage is unavailable.
  • The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2013

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Study notes and original source
2013Human comparative studyRussian-language source

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy · Conference report · company reproduction

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Results and tables

Reported findings and study design

Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.

Population or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.

Results · Russian conference reproduction, pp. 8–10, and matching English edition
MeasureResultComparison, timing and statistics
Total cholesterol7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4.Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.
VLDL cholesterol1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07.Both adjunctive groups are marked significant versus standard care.
Reported fatigue64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%.Only the four-product group is marked significant versus standard care in the fatigue row.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
Source reviewed
Authors’ conference material, Russian reproduction, PDF pages 8–10, methods and Tables 1–2. English and Russian editions describe the same comparison.
Study limitations
  • The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten.
  • Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods.
  • The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified.
  • Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible.
  • The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2019

Zhenoluten and Endoluten in women with reduced reproductive function

In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.

Study notes and original source
2019Human comparative studyRussian-language source

Zhenoluten and Endoluten in women with reduced reproductive function

Oral ovarian and pineal polypeptide combination · Conference report and expanded author report

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 9th European Congress of the International Association of Gerontology and Geriatrics, Gothenburg, 2019. Author material reproduced by Peptides.

In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.

Results and tables

Reported findings and study design

From 2013 to 2018, the Moscow center enrolled 276 women aged 34–38. The 214-person combination arm received oral Zhenoluten 20 mg each morning and Endoluten 10 mg every 72 hours for four months. The 62-person comparison received placebo. Neither group received hormone therapy.

Population or model 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.

Results · Expanded report by the congress authors, Tables 1–3, matched to the conference cohort
MeasureResultComparison, timing and statistics
Anti-Müllerian hormone at month four1.16 ± 0.18 ng/mL with the combination versus 0.82 ± 0.24 with placebo. Baselines were 0.76 ± 0.13 and 0.74 ± 0.12 ng/mL, respectively.
Estradiol at month four616.24 ± 69.42 pmol/L with the combination versus 209.26 ± 12.64 with placebo.
Pregnancies reported by months four through eight180/214 (84%) with the combination versus 8/62 (13%) with placebo. The expanded report supplies no live-birth outcomes or detailed follow-up accounting.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The differences come from a comparison with unspecified allocation and masking.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
Source reviewed
Conference reproduction, PDF pages 21–22, and expanded author report, Tables 1–3. Both describe the same participants.
Study limitations
  • Group assignment and masking are unspecified. The report combines two products, so the effect of either alone is unknown.
  • The pregnancy figures come from the authors’ expanded report. Live births, completeness of follow-up and maternal or neonatal safety data are unavailable.
  • The conference methods and expanded report agree on every-72-hour Endoluten. A recommendation elsewhere in the conference reproduction gives a different schedule.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2017

Tireogen and Endoluten as adjuncts in autoimmune thyroiditis

At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.

Study notes and original source
2017Human comparative studyEnglish abstract

Tireogen and Endoluten as adjuncts in autoimmune thyroiditis

Oral Tireogen, or Tireogen plus Endoluten, alongside standard treatment · Published conference abstract with author report

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · Innovation in Aging. 2017;1(Suppl 1):324. PMCID PMC6243877.

At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.

Results and tables

Reported findings and study design

89 patients received standard treatment, 42 added Tireogen and 87 added Tireogen plus Endoluten. The reported schedules were two Tireogen capsules daily and one Endoluten capsule every three days for four months. Capsule mass is unspecified. The levothyroxine unit in the reproduction is anomalous.

Population or model 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.

Results · Authors’ conference report reproduction, methods and Table 1, matched to the published abstract
MeasureResultComparison, timing and statistics
TSH at month fourStandard care 7.14 ± 0.86, Tireogen 4.09 ± 0.12, combination 3.94 ± 0.12 mIU/L. Shared baseline 8.84 ± 1.09.The table marks both adjunctive arms as significantly different from standard care.
Anti-thyroglobulin antibodies83.32 ± 3.28, 77.41 ± 1.18 and 18.91 ± 1.65 IU/L in the three groups, respectively.The table marks both adjunctive arms. The narrative describes no antibody effect with Tireogen alone.
Anti-thyroid peroxidase antibodies361.24 ± 12.4, 357.23 ± 11.41 and 29.16 ± 2.54 IU/L, respectively. The table gives no significance mark for this row.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The design leaves allocation unspecified and the table gives one shared baseline.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.
Source reviewed
Published 2017 conference abstract and authors’ reproduced report, PDF pages 16–17. The 2015 and 2017 presentations describe the same study program.
Study limitations
  • Allocation, masking and separate baseline values are unspecified. There was no Endoluten-only arm.
  • The table marks an anti-thyroglobulin difference for Tireogen alone, while the narrative says Tireogen alone did not affect antibodies. The anti-TPO row gives no significance mark.
  • The reproduction prints an anomalous levothyroxine unit. The exact background dose is uncertain.

Reviewed 2026-11-16.

Read the source ↗

Lab research · 2016

Vladonix, Endoluten and other peptides in cultured human blood cells

In cultured blood cells, Endoluten raised lysate IL-18 to 65.11 vs 39.06 pg/mL and IL-4 to 28.40 vs 12.24 pg/mL relative to saline.

Study notes and original source
2016In vitroFull text available

Vladonix, Endoluten and other peptides in cultured human blood cells

Six separately assayed peptide preparations supplied by the Khavinson laboratory. · Original journal article

M. V. Maksimenya, E. V. Fefelova, A. S. Bykova · Actual Problems of Humanities and Natural Sciences. 2016;12-3:97–100

Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.

Results and tables

Reported findings and study design

Saline-controlled cultures from 15 donors, 0.4 µg/mL for 24 hours. Lysate and supernatant were analyzed separately.

Population or model Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.

Dose, route and schedule

Cells were exposed to 0.4 µg/mL of each preparation or volume-matched saline for 24 hours at 37 °C. Cytokines were measured by ELISA in cell lysates and culture supernatant.

Protocol source ↗ · Original journal PDF, methods, Table 1 and culture-supernatant results

Results · Original journal PDF, methods, Table 1 and culture-supernatant results
MeasureResultComparison, timing and statistics
Vladonix · lysate IL-1866.48 vs 39.06 pg/mLMedian with Vladonix versus saline. · p < 0.001
Vladonix · lysate IL-1RA3,765 vs 5,228 pg/mLMedian with Vladonix versus saline. · p = 0.006
Endoluten · lysate IL-18 and IL-465.11 vs 39.06 and 28.40 vs 12.24 pg/mLEndoluten versus saline. · p = 0.02 and p < 0.001, respectively.
Crystagen and Cortexin · lysate IL-1875.10 and 60.02 vs 39.06 pg/mLEach preparation versus saline. Crystagen’s printed interval is inconsistent. · p = 0.004 and p = 0.04, respectively.
Vilon · lysate TNF-α and IL-1RA904.04 vs 598.05 and 4,056 vs 5,228 pg/mLVilon versus saline. · p = 0.045 and p = 0.02, respectively.
Epitalon · lysate IL-1RA4,346 vs 5,228 pg/mLEpitalon versus saline. · p = 0.047
Culture supernatantEndoluten IL-18 +33.46% and Vilon TNF-α +41.13%These were the only significant supernatant changes reported. Neither of the two Vladonix lysate findings was reported as significant in supernatant. · p = 0.02 and p = 0.035, respectively.
Table 1 · cell-lysate cytokines
Table 1 · cell-lysate cytokines
PreparationIL-18 (pg/mL)TNF-α (pg/mL)IL-4 (pg/mL)IL-1RA (pg/mL)
Saline39.06598.0512.245,228
Vladonix66.48*706.5417.623,765*
Endoluten65.11*429.0228.40*4,860
Crystagen75.10*505.2620.474,772
Vilon34.74904.04*9.964,056*
Epitalon30.62548.009.504,346*
Cortexin60.02*693.0015.044,921

Printed medians. Asterisks mark comparisons with saline at p < 0.05. The Crystagen IL-18 interquartile interval is printed as 66.46–70.62, which excludes the printed median.

The experiment measures cytokine concentrations after direct contact with cells. The clinical meaning and relevance to swallowing a capsule remain unknown.

Source for these results ↗ · Reviewed 2026-11-13

Population / setting
Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Source reviewed
Original journal PDF, methods, Table 1 and culture-supernatant results
Study limitations
  • The volunteers donated blood and did not receive treatment. Culture concentrations cannot establish oral exposure or clinical effects.
  • The Crystagen IL-18 median lies outside its printed interquartile interval. Some narrative percentages differ from ratios calculated from tabulated medians.

Reviewed 2026-11-13.

Read the source ↗

Experiment described in a patent · 2016

Endoluten plus Chonsurid: dental bone-healing method — RU2589265C2

The Endoluten case had higher final density but a longer reported healing time; the examples do not demonstrate faster healing.

Endoluten adjunct case · 20 mm defect: healing at 6.5 months; density 206 HU · One 66-year-old patient

Study notes and original source
2016Patent / reported experimentsFull text available

Endoluten plus Chonsurid: dental bone-healing method — RU2589265C2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Андрей Константинович Иорданишвили, Антон Анатольевич Сериков, Дмитрий Викторович Балин, Анна Геннадьевна Слугина, Владимир Владимирович Самсонов, Борис Лаврович Макеев, Людмила Юрьевна Орехова · RU2589265C2 · patent family 55959663

The Endoluten case had higher final density but a longer reported healing time; the examples do not demonstrate faster healing.

Results and tables

Reported patent results

Reported findings

The Endoluten case had higher final density but a longer reported healing time; the examples do not demonstrate faster healing.

Two dental-cyst case examples with Chonsurid, including one patient receiving branded Endoluten.

Population or model Two dental-cyst case examples with Chonsurid, including one patient receiving branded Endoluten.

Results · Description: timing observation and Examples 1 and 2; observed times retained despite the broader acceleration claim.
MeasureResultComparison, timing and statistics
Endoluten adjunct case20 mm defect: healing at 6.5 months; density 206 HUOne 66-year-old patient
Chonsurid-only example17 mm defect: healing at 4 months; density 177 HUOne 65-year-old patient
Other timing observationsPostoperative use or only 10–15 days before surgery reportedly lacked a marked density benefitDenominators and measured comparisons are absent

Different patients and defect sizes preclude a causal comparison. Higher density at a later time is not proof of accelerated healing or independent extract efficacy.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Two dental-cyst case examples with Chonsurid, including one patient receiving branded Endoluten.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • Endoluten is not automatically Epitalon or Epithalamin; the method cannot isolate the extract's contribution.
  • Different patients and defect sizes preclude a causal comparison. Higher density at a later time is not proof of accelerated healing or independent extract efficacy.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Observational study · 2016

Personified prevention of diseases under the conditions of the Far North

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

Study notes and original source
2016Uncontrolled human reportFull text available

Personified prevention of diseases under the conditions of the Far North

Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments · Journal publication

S. Trofimova, A. Trofimov, A. Koryakin, A. Chubukin, V. Ternovoy · Vrach. 2016;(6):64–66

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

Results and tables

Reported findings and study design

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Population or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Dose, route and schedule

One capsule of the assigned preparation daily for 20 days. Products were selected by risk assessment; all six products were not given to every participant.

Protocol source ↗ · Original PDF p.65

Results · Original publisher PDF pp.64–66; Table 2 visually checked
MeasureResultComparison, timing and statistics
Sick-leave certificates18 → 102014 → 2015; whole program
Days unfit for work119 → 602014 → 2015; whole program
Seasonal morbidityNo statistically reliable improvement reported
Narrative/table discrepancyNarrative 43.4% decrease; Table 2 gives 119 → 60 daysUnresolved source discrepancy; not interchangeable figures
Table 2 · Chronic-disease recurrence-related sick leave
Table 2 · Chronic-disease recurrence-related sick leave
Measure20142015
Sick-leave certificates1810
Days unfit for work11960

Historical comparison for the shared 113-worker program. Not preparation-specific results.

One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Source reviewed
Original publisher PDF methods and clinical table checked; table visually verified.
Study limitations
  • One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Reviewed 2026-11-01.

Read the source ↗

Comparison in people · 2011

Endoluten: clinical report on a tissue-derived preparation

In the dyshormonal myocardial dystrophy subgroup, estradiol was 101.3 pmol/L after Endoluten and 79.1 pmol/L after usual care. The report assessed several diagnoses separately.

Estradiol in the dyshormonal myocardial dystrophy subgroup · 101.3 ± 7.2 pmol/L with Endoluten versus 79.1 ± 4.2 pmol/L with conventional care. Shared baseline 65.4 ± 5.2 pmol/L. · Table 2 marks p < 0.05 versus conventional care.

Study notes and original source
2011Human comparative studyFull text available

Endoluten: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date

In the dyshormonal myocardial dystrophy subgroup, estradiol was 101.3 pmol/L after Endoluten and 79.1 pmol/L after usual care. The report assessed several diagnoses separately.

Results and tables

Reported findings and study design

163 patients across four diagnoses, 99 receiving adjunctive Endoluten and 64 conventional care. Courses were one to three capsules two to three times daily for 15–30 days.

Population or model 163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.

Results · Medical Center report, PDF pages 94–95, Tables 1–2
MeasureResultComparison, timing and statistics
Estradiol in the dyshormonal myocardial dystrophy subgroup101.3 ± 7.2 pmol/L with Endoluten versus 79.1 ± 4.2 pmol/L with conventional care. Shared baseline 65.4 ± 5.2 pmol/L.Table 2 marks p < 0.05 versus conventional care.
Follicle-stimulating hormone in the same subgroup46.8 ± 3.9 versus 71.6 ± 6.3 IU/mL, in the source’s printed units. Shared baseline 89.3 ± 3.5.Table 2 marks p < 0.05 versus conventional care.

The subgroup outcomes are short-term hormone measurements. The report does not explain the allocation method.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.
Source reviewed
Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
  • Subgroups must not be pooled into one efficacy result. This oral-preparation report cannot inherit long-term Epithalamin mortality findings. The linked page commercially reproduces the report.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-11-16.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗